Home Cart Sign in  
Chemical Structure| 1261609-26-0 Chemical Structure| 1261609-26-0

Structure of 1261609-26-0

Chemical Structure| 1261609-26-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1261609-26-0 ]

CAS No. :1261609-26-0
Formula : C7H7BrN2O
M.W : 215.05
SMILES Code : O=C(N)C1=CC(Br)=CC(N)=C1
MDL No. :MFCD18389345

Safety of [ 1261609-26-0 ]

Application In Synthesis of [ 1261609-26-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1261609-26-0 ]

[ 1261609-26-0 ] Synthesis Path-Downstream   1~1

  • 1
  • mutant of Actinosynnema pretiosum HGF073 [ No CAS ]
  • [ 42237-85-4 ]
  • yeast-malt-glucose medium [ No CAS ]
  • [ 1187832-07-0 ]
  • [ 1290117-36-0 ]
  • [ 1261609-26-0 ]
  • [ 1290117-39-3 ]
  • [ 1290117-35-9 ]
  • [ 1290117-37-1 ]
  • [ 1290117-38-2 ]
  • [ 1639866-80-0 ]
YieldReaction ConditionsOperation in experiment
0.01%; 0.01%; 0.1%; 0.01%; 0.1% In water; dimethyl sulfoxide;Microbiological reaction; Enzymatic reaction; Batchwise complementation of a growing culture (3 L) of the AHBA blocked mutant of A. pretiosum with <strong>[42237-85-4]3-amino-5-bromobenzoic acid</strong> (9) (3.9 g, 6 mmol/L medium) dissolved in DMSO according to the general protocol provided a crude ethyl acetate extract. This extract was prepurified by column chromatography (silica gel; ethylacetate) and afterwards by HPLC (C18-SP column) using a methanol-water gradient(20:80 100% methanol; 90 min). The fractions were further purified by HPLC (CNSPcolumn, acetonitrile/water, gradient 5:95 100% acetonitrile; 100 min). The new ansamitocin derivatives 22a (0.9 mg, 0.01%), 22c (0.9 mg, 0.01%) and 22e (0.6 mg,0.01%) were isolated as pure compounds. MS-analysis and retention times indicated formation of three additional ansamitocin derivatives 22b, 22d and 22f. These showed characteristic fragmentation patterns in the MS as established for the ansamitocins. In addition, also the detoxification products 3-amino-5-bromobenzamide 22g and 3-acetamino-5-bromobenzamide 22h were isolated in scales of 0.1% yield.
 

Historical Records

Technical Information

Categories